What if some medical decisions could be informed more quickly?
Preciphos is developing FoRe, a miniaturized immunological analysis platform designed to bring selected biological data closer to care environments, with speed, precision and operational efficiency.
closer to healthcare needs.
In many hospital, scientific and preclinical contexts, the time required to access biological data remains a critical factor. Analyses are still often centralized, costly, slow to obtain and sometimes poorly suited to the most fragile patients.
Centralized Analysis
Large-volume samples are sent to a distant laboratory, leading to substantial processing times and costs.
Point-of-Care Analysis
A portable platform enables specific analyses from a minimal blood sample, under medical or scientific oversight.
Data Available Faster
Certain biological information can be accessed directly within the care environment in just a few minutes.
Discover the latest developments at Preciphos and explore our insights into the scientific,
medical, and technological advances transforming access to biological data.
When biological information arrives too late, decision making has to wait.
Biological analyses still remain too often time-consuming, costly and dependent on centralized infrastructures. In sensitive situations,
this constraint can slow access to information that may be useful for medical or scientific teams.
More complex access for the most fragile patients or field environments
One drop of blood, less than 30 minutes:
a new analysis dynamic.
FoRe is a portable immunological analysis platform designed to bring selected laboratory-level capabilities closer to care or research environments, under hospital or scientific supervision.
It relies on proprietary technology combining miniaturization, assay chips and commercial reagents, with a clear objective: to make selected analyses faster, more accessible and less restrictive.
Faster, closer, more efficient:
a response to healthcare system pressures.
Preciphos addresses a dual challenge: accelerating access to selected biological information while reducing the technical, economic and logistical constraints associated with centralized analyses.
This approach opens the way to more mobile, more accessible biology, better suited to sensitive contexts such as pediatrics, neonatology, critical care, clinical research, field healthcare and preclinical environments
Reduce the time needed to obtain biological data relevant to decision-making.
One technological foundation.
Several perspectives to address.
Hospitals & decision-makers
Explore FoRe’s potential for healthcare institutions, medical departments, hospital laboratories and innovation teams.
Investors
Understand the medtech opportunity, business model, development trajectory and market outlook.
Scientists & research partners
Discover the principles behind the FoRe technology, its fields of application and resources available on request.
Institutional & industrial partners
Identify potential areas for collaboration across medical, research, NGO, veterinary and international development fields.
A platform designed
to evolve beyond a single use case.
A trajectory already underway.
Preciphos builds on a technology originating from ETH Zurich, initial active preclinical clients and collaborations with hospital and scientific partners. The company is preparing a progressive development trajectory, with first revenues expected in 2026-2027.
A demanding technology
driven by an experienced team.
Preciphos brings together scientific, medical, technical, financial and business profiles capable of taking a medtech innovation from research through to industrial and commercial deployment.
Chairmann / CEO
CTO
CMDO
CFO
Let’s discuss the perspectives
FoRe can open.
Are you an investor, hospital executive, scientist, institutional partner or industrial partner? Preciphos offers a qualified discussion to identify the right topics, documents and contacts.